Impact of Vaginal Estrogen in the Treatment of Symptomatic Mild Pelvic Organ Prolapse With Pelvic Floor Physical Therapy

Trial Profile

Impact of Vaginal Estrogen in the Treatment of Symptomatic Mild Pelvic Organ Prolapse With Pelvic Floor Physical Therapy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 15 Dec 2017

At a glance

  • Drugs Conjugated estrogens (Primary)
  • Indications Pelvic floor disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 27 Jan 2016 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019, according to ClinicalTrials.gov record.
    • 19 May 2015 Age limit revised from 40-60 years to 40-80 years.
    • 19 May 2015 Planned End Date changed from 1 Jul 2013 to 1 Dec 2018, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top